Seattle Genetics has been gaining recognition in the world of biotech research and is quickly becoming an authority on cancer treatment. It’s exactly what Dr. Clay Siegall hoped would become of his startup.
Seattle Genetics has recruited the best researchers in the field of cancer treatment to better develop drug therapy to better tailor treatment for patients. Dr. Siegall has been instrumental in the firm’s development, which builds upon his personal interest in the intersection between medicine and technology. It’s something that originated when a family member fell ill, and the reaction to traditional administration of chemotherapy wasn’t well received. He knew there had to be an alternative.
Seattle Genetics gets a great deal of its funding through the sale of medication, and more is awaiting approval from the FDA before it hits the market. This has increased the number of partnerships the firm has been able to obtain, furthering the Seattle Genetics brand by increasing its reach across the medical field. Dr. Siegall has noted that this continued involvement also assists in the FDA recognizing the importance of their research and give their medication more consideration in the evaluation process.
When getting the firm off the ground, Dr. Siegall noted that he had to personally engage investors and partners in order to have Seattle Genetics taken seriously in an emerging industry. Now that things are progressing positively, Siegall sees the future of his firm as secure, and that’s due in no small part to a culture of hard work and dedication to patient care that’s found throughout Seattle Genetics.
About Dr. Clay Siegall:
Dr. Clay Siegall graduated from George Washington University with a Ph.D. in Genetics, giving a platform that allowed him to serve as a member of the National Institutes of Health and the National Cancer Institute until 1999 when he departed these organizations to join Bristol-Myers Squibb Pharmaceutical Research Institute.
Dr. Siegall founded Seattle Genetics, a firm that researches and develops alternative cancer treatment methods that don’t incorporated traditional applications of chemotherapy. As Chief Executive Officer, President, and Chairman of the Board of Directors, Dr. Siegall applies his influence as an authority in the field of biomedical research to help secure more tan $675 million in public and private funding. Though is leadership, Seattle Genetics managed to have several medications approved by the FDA.